Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Massachusetts General Hospital: Clinical Trials & FDA Approval Profile

Massachusetts General Hospital (Boston, MA) sponsors 167 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 86 active protocols (56 recruiting now), 43 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.8%
Median Closed Enrollment vs National (145 pts)37 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Massachusetts General Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)167
Active Pipeline (Recruiting Now)86 (56)
Completed vs Stopped Early43 / 33 (19.8%)
Median Closed Actual Enrollment37 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Massachusetts General Hospital
Hospital Research SiteLocationShared Protocols
Massachusetts General HospitalBoston, MA143
Dana-Farber Cancer InstituteBoston, MA27
Beth Israel Deaconess Medical CenterBoston, MA27

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Massachusetts General Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06192615Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)Phase IIIRECRUITING
NCT06707493Ivosidenib as Post-HSCT Maintenance for AMLPhase IIRECRUITING
NCT04801797Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLPhase IIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mass General Brigham across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Massachusetts General Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI